The use of GenAI is intended to offer improved transparency about Gilead’s medicines to patients as well as internal staff. Credit: Sundry Photography / Shutterstock.com.

US companies Gilead Sciences and IT company Cognizant have announced an expansion of their collaboration to expedite digital transformation.

The agreement comprises renewal and expansion of services offered by Cognizant for $800m for the coming five years.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Under the partnership, Cognizant will handle Gilead’s international IT infrastructure, applications, advanced analytics and platforms.

The IT company will also take charge of programmes intended at expediting digital transformation for boosting client experience and quicker time to market for medicines of Gilead.

Through this deal, Gilead anticipates streamlining several segments of its business to expedite faster marketing of its assets for serious ailments, such as cancer, HIV and viral hepatitis.

Cognizant will also enable Gilead in expanding cloud operations and transforming business digitally utilising generative artificial intelligence (GenAI) and AI automation. 

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The usage of GenAI is intended to offer improved transparency about Gilead’s medicines to patients as well as internal staff across the globe. 

The Neuro IT solution of Cognizant will be used by Gilead to carry out AI automation innovation, enabling the latter to speed up the commercialisation of its products. 

Gilead Sciences senior vice-president and chief information officer Marc Berson said: “Over the past three years, Cognizant has demonstrated quality delivery, adaptability and dedication to Gilead’s success. 

“Through this collaboration, Cognizant has provided critical expertise to progress our digital transformation journey while enabling stable, secure operations. 

“This has allowed us to advance research and commercialization of transformative treatments for some of the world’s most challenging diseases.” 

The latest development comes after Gilead entered partnerships with the Clinton Health Access Initiative (CHAI) and the Penta ID network to speed up the development of dispersible HIV treatment for children.